title: Clinical and angiographic outcomes at more than 1 year after treatment of chronic total occlusions with the everolimus-eluting bioresorbable vascular scaffold.
abstract: OBJECTIVE
  Treatment of chronic total occlusion (CTO) with everolimus-eluting bioresorbable vascular scaffold (BVS) is safe and effective at short-term follow-up (FU). The current study investigated clinical and angiographic outcomes after treatment of CTO with BVS at >1 year.
  
  
  METHODS
  Thirty patients who underwent successful recanalization of 35 CTOs were included in this study. Quantitative coronary angiography (QCA) was performed at median FU period of 402 days. Clinical endpoints analyzed included all-cause mortality, cardiac death, non-fatal target vessel myocardial infarction, target vessel revascularization (TVR), symptom-driven target lesion revascularization (TLR), and BVS thrombosis.
  
  
  RESULTS
  QCA analysis revealed in-scaffold minimal luminal diameter of 2.14±0.50 mm and late lumen loss (LLL) of 0.38±0.54 mm. One cardiac death, 5 cases with TVR, and 3 cases with TLR were detected at median FU time of 542 days. No BVS thrombosis was observed.
  
  
  CONCLUSIONS
  The Absorb BVS was safe and effective in the treatment of CTO with acceptable LLL at mid-term FU, comparable to drug eluting stents.
authors.affiliation: Department of Cardiology, Bezmialem Foundation University, İstanbul, Turkey.
authors.forename: Aylin Hatice
authors.initials: AH
authors.lastname: Yamaç
authors.forename: Abdülkadir
authors.initials: A
authors.lastname: Yıldız
authors.forename: Meherrem
authors.initials: M
authors.lastname: Nasifov
authors.forename: Ahmet
authors.initials: A
authors.lastname: Taştan
authors.forename: Nemat
authors.initials: N
authors.lastname: Bashirov
authors.forename: Ömer
authors.initials: Ö
authors.lastname: Göktekin
mesh_terms: D000368:Aged; D017023:Coronary Angiography; D054059:Coronary Occlusion / Q000000981:diagnostic imaging / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D054457:Tissue Scaffolds; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068338:Everolimus